Agenda & Learning Objectives

 Participants in this program will be able to:
  • Explore new therapies in IBD with emphasis on individualized therapy and strategic sequencing
  • Discuss treatment options in inflammatory bowel disease patients with cancer
  • Examine the roles of therapeutic drug monitoring and individualized dosing across biologic agents
Time
Title/Topic
Speakers/Facilitators
11:00 EST  Opening Remarks 
Welcome, program objectives
CO-CHAIRS: 
Alain Bitton & John Marshall

(1) Biologics - Matching Drugs to Patients

11:10 EST 1.1 Interactive Case Presentation

Objectives:
  • Case to highlight learning objectives of the Plenary session
MODERATOR:
John Marshall
11:30 EST 1.2 State-of-the-Art Plenary Presentation
Biologics - Matching Drugs to Patients
Objectives:
  • Treatment sequencing
  • New agents
  • Individual therapies
William Sandborn
University of California

11:50 EST

1.3 Expert Panel Discussion/Q&A

Objectives:
  • Moderator will receive questions from the audience and guide the Expert Panel to clarify key issues from the plenary presentation
  • Panel will respond to questions from the audience and discuss controversial management issues in IBD
MODERATOR:
John Marshall

 
PANEL: 
Vipul Jairath
Jennifer Jones
William Sandborn
Laura Targownik
12:10 EST E-Mentoring in IBD Lit Quiz – Round One
 
MODERATOR:
Alain Bitton

(2) Cancer and IBD

12:15 EST 2.1 Case-based Workshop Breakout Session

Objectives:
  • Case to highlight learning objectives of the Plenary session
MODERATOR:
Alain Bitton

FACILITATORS:
TBC
12:45 EST
2.2 State-of-the-Art Plenary Presentation
Does my treatment cause cancer?
Objectives:
  • If you have cancer, what treatment?
  • How have the new biologics changed the landscape
  • Screening
  • Pre-existing malignancy and what therapies to use
Millie Long
University of North Carolin
13:05 EST 2.3 Expert Panel Discussion/Q&A

Objectives:
  • Moderator will receive questions from the audience and guide the Expert Panel to clarify key issues from the plenary presentation
  • Panel will respond to questions from the audience and discuss controversial management issues in IBD
MODERATOR:
Alain Bitton

PANEL:
Charles Bernstein
Brian Bressler
Karen Kroeker
Millie Long
13:25 EST Stretch Break (yoga pants optional) (10 mins)  

(3) Proactive/Reactive TDM

13:35 EST 3.1 Case-based Workshop Breakout Session

Objectives:
  • Case to highlight learning objectives of the Plenary session

MODERATOR:
Anne Griffiths

FACILITATORS:
TBC

14:05 EST 3.2 State-of-the-Art Plenary Presentation 
Modern use of TDM across agents
Objectives:
  • Overview of the current lay of the land with all agents
  • Who, How, When and Why?
Niels Vande Casteele
University of California
14:25 EST 3.3 Expert Panel Discussion/Q&A

Objectives:
  • Moderator will receive questions from the audience and guide the Expert Panel to clarify key issues from the plenary presentation
  • Panel will respond to questions from audience and discuss controversial management issues in IBD
MODERATOR:
Anne Griffiths

PANEL:
 
Waqqas Afif
Reena Khanna
Cynthia Seow
Niels Vande Casteele
14:45 EST E-Mentoring in IBD Lit Quiz – Round Two MODERATOR:
Alain Bitton
14:50 EST Richard Fedorak Mentoring in IBD Award of Distinction TBA
15:00 EST Closing Remarks – Evaluation, Adjournment CO-CHAIRS: 
Alain Bitton &
John Marshall

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.